Extracellular vesicle cargoes as diagnostic and prognostic biomarkers of malignant pleural effusion
Active Grant Awarded
- Award ID
- R01CA316439
- Recipient
-
Vanderbilt University Medical Center UEI GYLUH9UXHDX5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $726,231
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 3% complete
- Place of performance
- Forest Hills, TN 37215, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Vanderbilt University Medical Center (doing business as Vumc) $726,231 on September 23, 2026, under Grant R01CA316439. The award falls under the Cancer Detection and Diagnosis Research program (CFDA 93.394), which funds screening, early detection, and diagnostic methods for predicting the course of cancer.
The funded project, "Extracellular Vesicle Cargoes as Diagnostic and Prognostic Biomarkers of Malignant Pleural Effusion," aims to identify extracellular vesicle cargo signatures that distinguish cytology-negative malignant pleural effusions from non-malignant effusions. The source notes that standard cytologic examination of pleural fluid identifies only roughly 50% of malignant effusions. The first specific aim is to identify differentially expressed extracellular vesicle cargo. The work draws on a growing pleural fluid biorepository (current N=513) that includes cytology-positive and cytology-negative malignant and non-malignant effusions, along with longitudinal samples carrying tumor-specific and clinical data.
The obligated amount is $726,231. The period runs from the September 23, 2026 award date to an ultimate completion date of August 31, 2031. Place of performance is Forest Hills, Tennessee 37215. The recipient is a child entity of The Vanderbilt University, identified by UEI GYLUH9UXHDX5. The source does not identify sub-recipients for this award.
Description
- Abstract
- /summary: an estimated 1.5 million pleural effusions are diagnosed in the united states annually, among these 200,000 are malignant pleural effusions (MPE). There is an important unmet clinical need for better diagnostic tests because the standard test, cytologic examination of pleural fluid (PF), only identifies ~50% of MPE and increases marginally upon serial sampling. Therefore, invasive and morbid procedures such as thoracoscopic pleural biopsy are often required, placing patients at risk for complications and delaying diagnosis and treatment. To address this unmet need, we have examined the potential of tumor cell products, specifically extracellular vesicles (EVS), as novel molecular biomarkers for MPE diagnosis. In previous studies, we characterized EVS in cell-free PF of cytology-positive carcinoma induced MPE and identified and validated distinct EV microrna (MIRNA) signatures discriminating MPE from non-malignant pleural effusion (non-MPE). In addition, we have identified an association between specific EV-mirnas and cancer-specific survival. Furthermore, we have examined the pleural fluid protein EV-cargo and identified increased expression of CD326 in lung and breast adenocarcinoma MPE compared to non-MPE. Our recent preliminary data indicates that cytology-negative carcinoma derived MPE fluid is an abundant source of tumor-derived EVS, whose MIRNA cargo can differentiate MPE from non-MPE. The critical next step is to identify EV-cargo signatures that identify cytology-negative mpes from non-MPE, where current tests fail or are highly invasive. To accomplish this goal, we will leverage samples from a growing PF biorepository (current N=513) that includes cytology positive and negative MPE and non-MPE, as well as longitudinal samples with detailed tumor- specific and clinical data. Specific aims will: 1) identify differentially expressed extracellular MIRNA in cytology- negative MPE for development of a diagnostic classifier, 2) identify differentially expressed EV protein cargo in cytology-negative MPE for development of a diagnostic classifier, 3) validate extracellular MIRNA/protein classifier in an independent MPE VS non-MPE cohort, and 4) identify longitudinal extracellular MIRNA/protein expression correlation with prognosis. If successful, this work will change the current paradigm by adding extracellular vesicle-based diagnostic methods to complement cytology examination of pleural fluid, potentially saving thousands of patients every year in the U.S. From undergoing invasive medical procedures. In addition, these studies could pave the way for future trials focused on monitoring disease progression, identifying response to therapy, and investigating the pathobiology of malignant pleural invasion and metastasis.
Quick answers
Who received award R01CA316439?
R01CA316439 was awarded to Vanderbilt University Medical Center by National Cancer Institute (National Institutes of Health) on September 23, 2026.
How much is award R01CA316439 worth?
$726,231 has been obligated on R01CA316439.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award